Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.

IF 4.5 3区医学 Q2 IMMUNOLOGY

Current Opinion in HIV and AIDS Pub Date : 2023-11-06 DOI:10.1097/coh.0000000000000833

Jacqueline Capeau, Claire Lagathu, Véronique Béréziat

引用次数: 0

Abstract

Antiretroviral therapy (ART) has long been implicated in fat alterations and weight variations leading to cardiometabolic consequences. Recent largely prescribed antiretrovirals (ARVs) from the integrase-strand-transfer-inhibitor (INSTI) class have been associated with excessive weight gain/obesity in a minority of persons with HIV (PWH). As well, in the nucleoside reverse transcriptase inhibitors (NRTI) class, tenofovir-alafenamide (TAF), often replacing tenofovir-disoproxil-fumarate (TDF), has been associated with weight gain, a worrying concern in the present worldwide obesogenic environment. The respective role of the different ARV, the risk factors and the mechanisms remain questionable.

查看原文本刊更多论文

关于抗逆转录病毒疗法对艾滋病毒感染者体重增加和肥胖所起作用的最新数据。

长期以来，抗逆转录病毒疗法（ART）一直被认为与导致心脏代谢后果的脂肪改变和体重变化有关。在少数艾滋病病毒感染者（PWH）中，近期主要处方的整合酶-链转移抑制剂（INSTI）类抗逆转录病毒药物（ARV）与体重过度增加/肥胖有关。此外，在核苷类逆转录酶抑制剂（NRTI）中，替诺福韦-阿拉非那胺（TAF）经常取代替诺福韦-二异丙嗪-富马酸盐（TDF），也与体重增加有关，这在目前全球肥胖的大环境下令人担忧。不同抗逆转录病毒药物各自的作用、风险因素和机制仍存在疑问。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in HIV and AIDS IMMUNOLOGY-INFECTIOUS DISEASES

CiteScore

7.40

自引率

7.30%

发文量

115

审稿时长

6-12 weeks

期刊介绍： Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in HIV and AIDS features hand-picked review articles from our team of expert editors. With six disciplines published across the year – including HIV and ageing, a HIV vaccine, and epidemiology – every issue also contains annotated reference detailing the merits of the most important papers.